Verdict No. 3103 · Search date 2026-09-15 · Methodology v1.0
Biotin , sole-active oral product,
does it really help with Increased target-area non-vellus hair density in adult androgenetic alopecia, with separate sex strata?
30-Second Summary
?
Evidence Grade ? · Safety caution
ChatGPT source review and self-verification · Codex technical integration
Cutoff 2026-09-15. The male/female target strata and proposed comparators are question definitions, not verified trial values. Exact formulation, dose, duration, baseline biotin status, measurement definition, time, arm denominators, between-group effect, CI and MCID remain unverified. Existing records 009, 866 and 1639 were not modified.
Caution: biotin can cause falsely high or low results in selected assays. NIH describes thyroid-test interference within 24 hours of a single 10 mg dose and interference in selected TSH and NT-proBNP assays in 6 healthy adults taking 10 mg/day for 1 week. FDA warns of falsely low results in susceptible troponin assays. These are assay-, exposure- and time-specific observations, not a universal withdrawal interval or toxicity threshold. High-dose long-term hair-use safety in pregnancy, lactation, children and hepatic or renal disease is unverified. This assessment gives no personal dosing, discontinuation or test-scheduling instruction. [S06][S07]
What the
research showsWithin the recorded search scope, no directly eligible result verified that oral biotin alone increases target-area non-vellus density versus a matched-background control in male or female androgenetic alopecia, assessed separately. The current grade is ?, with no numerical score. This is not a finding of no effect. [S01][S02][S03][S04][S05][S10][S11]
research showsWithin the recorded search scope, no directly eligible result verified that oral biotin alone increases target-area non-vellus density versus a matched-background control in male or female androgenetic alopecia, assessed separately. The current grade is ?, with no numerical score. This is not a finding of no effect. [S01][S02][S03][S04][S05][S10][S11]
What the
ads claimImprovements in hair counts, diameter, photographs or satisfaction with biotin-containing products cannot be relabelled as non-vellus density improvement in male- or female-pattern alopecia. Natural origin does not mean effects of other extract constituents have been isolated. [S04][S05]
ads claimImprovements in hair counts, diameter, photographs or satisfaction with biotin-containing products cannot be relabelled as non-vellus density improvement in male- or female-pattern alopecia. Natural origin does not mean effects of other extract constituents have been isolated. [S04][S05]
Four separate assessment dimensions
| Effect direction and size | No directly eligible sex-stratified between-group non-vellus-density result for oral biotin monotherapy was verified |
|---|---|
| Evidence certainty | ? is scoped direct-evidence uncertainty, not no effect |
| Applicability | Adults with diagnosed androgenetic alopecia; male and female strata separate; oral biotin as the sole active ingredient; matched-background placebo, no treatment, or usual care |
| Safety | Caution |
B / P / null / null / null / null / null; score and strength count null
Useful facts when choosing a product
- Manufacturing source, chemical form, batch, purity and excipients of an eligible sole-active product are unverified.
- Objectively deficient correction is separate from androgenetic alopecia. An absent baseline assay is not evidence of adequate status.
- The absence of an NIH upper intake level is not used as unlimited safety assurance or a treatment dose. [S06]
Chamgap Semantic Classification Code
Permanent code issued
S.biotin.oral.adult-androgenetic-alopecia-non-vellus-hair-density.increase.placebo-no-treatment-or-usual-careSubstances and nutrients > Biotin (vitamin B7), sole active ingredient > Oral > Target-area non-vellus hair density in sex-stratified adult androgenetic alopecia > Increase claim > Matched-background placebo, no treatment, or usual care
Male and female strata remain separate and only target-area non-vellus density is fixed. Deficiency correction, other alopecia causes, growth speed, diameter, photographs, satisfaction, and multicomponent products remain separate boundaries. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Biotin (vitamin B7), sole active ingredient |
| Source or part used | Not verified: no eligible trial establishes the source, manufacturing origin or exact chemical form. |
| Formulation or processing | Sole-active oral product is the question boundary; actual tablet/capsule, batch, purity and excipients are not verified. |
| Route | Oral, fixed by the question; topical and injectable exposure excluded. |
| Dose | Not verified: eligible regimen dose, frequency and total intake. |
| Duration | Not verified: eligible treatment duration and assessment time. |
| Population | Adults with diagnosed androgenetic alopecia; male and female strata separate, no pooled effect; objectively deficient correction and other alopecia causes excluded. |
| Effect or condition | Increase target-area non-vellus hair density. |
| Primary endpoint | Between-group change difference in target-area non-vellus density preferred; endpoint difference separate; definition, site, unit, time and denominator not verified. |
| Comparator | Matched-background placebo, no treatment and usual care considered separately; actual eligible comparator not verified. |
| Duplicate-detection key | biotin|single-active-oral|diagnosed-adult-aga|male-female-unpooled|target-area-non-vellus-density|matched-placebo-no-treatment-usual-care|dose-duration-unverified |
What the research actually shows
Patel reports a 90-day trial with 105 randomized and 97 completed healthy adults with nonpathological hair, skin and nail concerns. Even the biotin-labelled arm used Sesbania grandiflora extract, with 250 mg extract and 1.25 mg biotin equivalent per capsule. This exposure was not adopted as an established effective sole-active biotin regimen. [S05]
Why this is classified as ?
The question is classified as clinical efficacy B and treatment target P under the supplied rubric. Hair restoration is the target itself; observer measurement alone does not make it a surrogate. With no verified eligible result, grading stops at stage 0, ? and score null. Replication, independence, effect, bias, precision and the strength count remain unscored null. Related human studies do exist.
Counterpoint. Unverified evidence is distinct from no effect. Healthy-person and multicomponent studies are not repeated refutations in male or female androgenetic alopecia. Failed registration or original-text access was not interpreted as evidence of no results or study termination. [S03][S04][S05][S10][S11]
Rejudgment record. Direct eligible result not verified — Original rubric stage 0; bounded search scope
Stored scoring profile
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests |
Stored derived and displayed grades match; this is not a current recalculation or validity check (?).
Review performed and remaining limitations
Twelve-axis boundaries were checked against records 009, 866 and 1639, separating healthy-person growth speed, multicomponent products, deficiency correction and other hair outcomes
Eligible product form, formulation, dose, duration, diagnostic criteria, baseline status, sex-specific denominators, assay method, between-group effect, CI, P value and MCID remain unverified
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Valentim 2024 healthy-male crossover | open randomized-sequence self-controlled crossover | See trial_families/numeric_evidence for denominators; target endpoint denominator unverified. | none declared | Separate outcome; not directly eligible for target AGA non-vellus density. | Excluded for healthy population, growth-speed outcome and crossover comparison. Both nonsignificant monotherapy and positive combination findings retained, not used as AGA density effects. | Excluded from direct efficacy grading |
| Ablon 2015 multicomponent marine-protein supplement | Design not newly verified; safety or inherited extract | See trial_families/numeric_evidence for denominators; target endpoint denominator unverified. | manufacturer support in inherited extract; not newly adjudicated | Separate outcome; not directly eligible for target AGA non-vellus density. | Excluded for multicomponent marine-protein product and self-perceived thinning; inherited extraction only. | Excluded from direct efficacy grading |
| Patel 2025 botanical biotin / botanical biotin-silica | randomized double-blind placebo-controlled three-arm single-center trial | See trial_families/numeric_evidence for denominators; target endpoint denominator unverified. | product manufacturer and CRO employment disclosed; full sponsor funding contract not verified | Separate outcome; not directly eligible for target AGA non-vellus density. | Excluded for healthy cosmetic population, botanical extract and unverified non-vellus definition. Positive findings and manufacturer employment retained. | Excluded from direct efficacy grading |
| Zhang 2020 assay interference | Design not newly verified; safety or inherited extract | See trial_families/numeric_evidence for denominators; target endpoint denominator unverified. | Not verified | Separate outcome; not directly eligible for target AGA non-vellus density. | Assay-interference safety context only, not direct hair efficacy. | Excluded from direct efficacy grading |
| NCT06605768 unresolved registered supplement lead | Design not newly verified; safety or inherited extract | See trial_families/numeric_evidence for denominators; target endpoint denominator unverified. | Not verified | Separate outcome; not directly eligible for target AGA non-vellus density. | Official full record/results inaccessible. Unverified eligibility, not a negative result. | Excluded from direct efficacy grading |
Receipt — 12 References
Evidence access cutoff: 2026-09-15. Each citation states its actual access level (full-text transcription, abstract, index, or other) and remaining limitations. Bibliographic checking does not certify the study results or treatment efficacy.
A Review of the Use of Biotin for Hair Loss (Patel, Swink, Castelo-Soccio, 2017)
Review, not an RCT. Its old case-report synthesis is discovery context, not a current exhaustive absence conclusion.
checkedBiotin for Hair Loss: Teasing Out the Evidence (Yelich et al., 2024)
PMC returned an access challenge; publisher/repository attempts failed. Historical trial details not newly verified. No DOI invented.
checkedEfficacy of 5% topical minoxidil versus 5 mg oral biotin versus topical minoxidil and oral biotin on hair growth in men (Valentim et al., 2024)
Full PMC text and HTML table checked; population and endpoint clarified for the new question. No original PDF downloaded.
checkedAblon 2015 marine-protein supplement study in women with self-perceived thinning hair
Multicomponent product and self-perceived thinning: not biotin-only diagnosed AGA. Old numerical efficacy estimates were not imported.
checkedThe Role of Sesbania grandiflora-Derived Biotin and Bambusa arundinacea-Derived Silica Extracts in Promoting Hair, Skin, and Nail Health (Patel et al., 2025)
Publisher PDF and screenshots of pp3–4 checked. DOI is printed in the PDF; PMID/PMCID cross-checked in indexed metadata, not a complete current PubMed record. Registry history unavailable.
checkedNIH Office of Dietary Supplements: Biotin—Health Professional Fact Sheet
Official page displayed updated January 10, 2022. Used for current accessible safety information, not as an up-to-date exhaustive trial review. Specific studies cited here were not newly claimed as full-text verified.
checkedFDA: Biotin Interference with Troponin Lab Tests—Assays Subject to Biotin Interference
Existing source identifier/URL reused and current official text checked for this task safety context; selected assays, not all assays. No frequency estimate.
checkedAssessment of biotin interference in thyroid function tests (Zhang et al., 2020)
Current PMC access challenge and empty PubMed output. Retained as supporting historical safety context, not a newly verified universal washout recommendation.
checked2026 Dermato systematic-review lead in existing 009
Author details and full included-study list not newly verified; discovery only, not an independent trial or basis for efficacy scoring.
checkedClinicalTrials.gov NCT06605768—hair supplement study lead
Indexed title/record pointer found, but full current protocol/results not accessible. Product single-ingredient status, AGA eligibility and non-vellus outcome not verified. Commercial snippets not treated as authoritative trial facts.
checkedClinicalTrials.gov NCT05972512—registration cited by Patel 2025
Bundled with S05, never counted as replication. Registry content/history not retrieved; prospective outcome hierarchy not independently verified.
checkedThe Infatuation With Biotin Supplementation: Is There Truth Behind Its Rising Popularity? (Soleymani et al., 2017)
Narrative review, not an RCT. No new original access claimed.
checkedContent is publishable with uncertainty; Codex performed only identifier, format, build, and deployment checks.
Technical integration by: Codex · Evidence date: 2026-09-15 · Corrections: none
Technical integration by: Codex · Evidence date: 2026-09-15 · Corrections: none
Cite this verdict
[Chamgap] Oral biotin alone × non-vellus hair density in adult androgenetic alopecia — Evidence Grade ?. 12 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/oral-biotin-alone-androgenetic-alopecia-non-vellus-density/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.